Literature DB >> 15249497

Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

Vallerie V McLaughlin1, Kenneth W Presberg, Ramona L Doyle, Steven H Abman, Douglas C McCrory, Terry Fortin, Gregory Ahearn.   

Abstract

Although idiopathic pulmonary arterial hypertension is perceived as a progressive disease with a uniformly poor outcome, the natural history of disease is heterogeneous, with some patients dying within months of diagnosis and others living for decades. The course of the disease has also been altered by advances in medical therapies. The outcome of patients with other types of pulmonary arterial hypertension (PAH) has been less well characterized. Assessment of prognosis of such patients is important, as it influences both medical therapy and referral for transplantation. This chapter will provide evidence based recommendations to assess the prognosis of patients with PAH.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15249497     DOI: 10.1378/chest.126.1_suppl.78S

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  107 in total

Review 1.  Pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

Review 2.  Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Authors:  Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Audrey Courboulin; Steeve Provencher; Sébastien Bonnet
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

3.  Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension.

Authors:  Aránzazu Campo; Stephen C Mathai; Jérôme Le Pavec; Ari L Zaiman; Laura K Hummers; Danielle Boyce; Traci Housten; Hunter C Champion; Noah Lechtzin; Fredrick M Wigley; Reda E Girgis; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2010-03-25       Impact factor: 21.405

4.  Pulmonary arterial hypertension.

Authors:  Sheng Chin Wu; Sergio Caravita; Elisabetta Lisi; Simona Pierini; Viola Dadone; Sarah E Todd; Francesco Gentile; Maria Beatrice Secchi
Journal:  Intern Emerg Med       Date:  2009-12       Impact factor: 3.397

5.  A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary hypertension.

Authors:  Nika Skoro-Sajer; Irene M Lang; Evis Harja; Meinhard P Kneussl; Wendy Gin Sing; Simon J R Gibbs
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

6.  Noninvasive assessment of right heart function and hemodynamics during exercise in patients with pulmonary arterial hypertension.

Authors:  Michelle L Freeman; Carolyn Landolfo; Robert E Safford; Cesar A Keller; Michael G Heckman; Charles D Burger
Journal:  South Med J       Date:  2013-02       Impact factor: 0.954

7.  An unexpected diagnosis in a dyspnoeic patient with primary Sjogren syndrome.

Authors:  Ali Raza Rajani; Kosar Hussain; Fahad Omar Baslaib; Kabad N S Rao
Journal:  BMJ Case Rep       Date:  2013-01-17

Review 8.  [Systemic sclerosis. Objectives for the treatment].

Authors:  B Maurer; M Walder; R E Gay; S Gay; O Distler
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

9.  Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension.

Authors:  Kwon-Ho Hong; Young Jae Lee; Eunji Lee; Sung Ok Park; Chul Han; Hideyuki Beppu; En Li; Mohan K Raizada; Kenneth D Bloch; S Paul Oh
Journal:  Circulation       Date:  2008-07-28       Impact factor: 29.690

10.  Echocardiographic and hemodynamic predictors of mortality in idiopathic pulmonary fibrosis.

Authors:  Belinda N Rivera-Lebron; Paul R Forfia; Maryl Kreider; James C Lee; John H Holmes; Steven M Kawut
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.